Pharmacovigilance: The Role Of Pharmaceutical Companies To Protect Patients From Adverse Drug Reactions by Nukala, Srikanth
Harrisburg University of Science and Technology
Digital Commons at Harrisburg University
Dissertations and Theses Project Management (PMGT)
8-2017
Pharmacovigilance: The Role Of Pharmaceutical
Companies To Protect Patients From Adverse
Drug Reactions
Srikanth Nukala
Harrisburg University of Science and Technology
Follow this and additional works at: http://digitalcommons.harrisburgu.edu/pmgt_dandt
Part of the Management Information Systems Commons, and the Management Sciences and
Quantitative Methods Commons
This Thesis is brought to you for free and open access by the Project Management (PMGT) at Digital Commons at Harrisburg University. It has been
accepted for inclusion in Dissertations and Theses by an authorized administrator of Digital Commons at Harrisburg University. For more information,
please contact drunyon@harrisburgu.edu, ereed@harrisburgu.edu.
Recommended Citation
Nukala, S. (2017). Pharmacovigilance: The Role Of Pharmaceutical Companies To Protect Patients From Adverse Drug Reactions. Retrieved
from http://digitalcommons.harrisburgu.edu/pmgt_dandt/21
  
 
 
 
 
 
 
 
 
 
 
Pharmacovigilance: The Role Of Pharmaceutical Companies To Protect Patients From Adverse 
Drug Reactions 
. 
 
Srikanth Nukala 
Harrisburg University 
GRAD 695 PGMT 
 
 
 
 
                                                                    
 
1.0 Abstract .......................................................................................................................... 2 
2.0 Introduction ................................................................................................................... 3 
3.0 Problem Statement and Justification ............................................................................. 7 
4.0 Literature Review .......................................................................................................... 9 
5.0 Methodology ................................................................................................................ 16 
6.0 Proposed work plan…………………………………………………………………..25 
7.0 References ................................................................................................................... 32 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.0 Abstract 
Objective:  
Health Care Professionals (HCPs) play a vital role in the early detection, assessment and 
reporting of Adverse Drug Reactions (ADRs) to the Regulatory Health Authority or 
Pharmaceutical Manufacturer. It’s always important that HCPs should improve continuously 
about their knowledge, attitude and their practice towards Pharmacovigilance and ADR 
reporting. The main goal of the research study is to evaluate whether if pharmacovigilance 
training provided by the Pharmaceutical Company will improve the HCP’s knowledge, their 
attitude and practice improves towards Pharmacovigilance and ADR reporting (Alan, Melike, 
Sule , Burcu, & Yusuf , 2013). The training is provided through the electronic learning 
management system. The learning management system (LMS) will be implemented using the 
Waterfall Methodology (Foreman, 2013).  
 
 
 
 
 
 
 
 
 
                         
                                                     2.0 Introduction 
In developing countries, the safe use of the medicines and safeguard of the patients are given 
most priority. The introduction of new medications has changed the path in which diseases are 
overseen and controlled, and much of the time this has been a significantly useful for better 
evolution (Alan, Melike, Sule , Burcu, & Yusuf , 2013). Though there are controlled processes 
in place, there is a need to share the risks and associated benefits of the safe use of the 
medicines. However, recent statistics per shows there are considerable increase number of 
adverse drugs reaction to medicines and yet need to have proper process in place to prevent 
them from cause of illness, disability and even death. ADRs are one of the major drug related 
problems associated with pharmacotherapy causing high incidence of mortality and morbidity 
around the world.  It has been become a major health problem around the globe. According to 
the Institute of Medicine in the United States (2000) reported that reported that between 44,000 
and 98,000 deaths occur annually from medical errors. Out of which is 7000 deaths mainly due 
to the ADRs. Even in developed countries, this has been significant problem (Koh, 2014). The 
ADRs has made burden on the healthcare systems and the community as well. 
 
The epidemic diseases such as Human Immunodeficiency Virus/ Acquired 
Immunodeficiency Syndrome and Tuberculosis and malnutrition that are more predominant in 
the African countries, is largely chance of risks of certain ADRs in patients (Mehta, M Dheda, 
& Steel, 2014). The other reason for the increase of the ADRs due to misuse of the medication 
self-medication of the Over the Counter medicines and medication errors that are the most 
common underlying reasons in underdeveloped countries. 
 
The ADRs, is causing become major problem in the health care system that needs to be 
addressed immediately at different levels of the health care system. The common factors that 
are contributing for this problem is the lack of awareness among health care providers about the 
risks associated with drugs and misclassification of the ADRs as other diseases or the causal 
conditions (Shamim, Sharib, Mahi, & Raza, 2016). However, the half of the ADRs that occur in 
the patients could be preventable with improved prescribing, administration, monitoring and 
conformance. 
Consequently, need to have proper process in place to reduce the occurrence of ADRs 
that in turn improves the public health. It is a well-established fact, however, that in the clinical 
trials pharmaceutical companies do not have the statistical power to detect rare ADR’s nor do 
they have significant follow-up to identify delayed adverse drug reactions or effects from long-
term exposure (Sharrar & Dieck, 2013). In view of this, pharmacovigilance plays a prominent 
role in establishing the safety profile of marketed drugs, as pre-marketing clinical trials are 
often not.  
The success or failure of the Pharmacovigilance systems would be mainly depending 
upon on the reporting process of the ADRs and evaluation of ADRs. For pharmaceutical 
products, a proper ADR reporting process should be in place and it should be the integral part 
of the Pharmacovigilance program which is the efficient process of obtaining information 
especially new and serious ADRs (Foreman, 2013). For this information, pharmaceutical 
companies more rely on the HCPs to identify and report the Suspected ADRs to the competent 
health authorities. Therefore, most companies considered them as the main contributor for the 
ADR reports and believe them as genuine sources. Thus, the HCP are the contributor of 
spontaneous ADR reports and important roles for following 
• Identification 
• Assessment 
• Spontaneous reporting. 
Per the survey conducted by various researchers shows that the ADR could be avoided 
only when the HCPs have great knowledge and awareness of the pharmacovigilance and ADR 
reporting process (Mehta, M Dheda, & Steel, 2014). In the undeveloped countries shows 
pharmacovigilance training by the companies is very minimal and that’s the risk associated to 
the products in those countries is very high and had been huge impacted on the patient 
population.  
I work in a Pharmaceutical Industry has a Pharmacovigilance Compliance Project 
Manager. As part of my job responsibilities, the Adverse drugs reaction related to our product 
received from the different sources such as Patient, Health Care professional or from 
Regulatory authorities are entered the drug safety data base as per the company’s policies and 
procedures.  The information received are identified, assessed and evaluated whether the 
adverse event whether it’s known or unknown risks. If the AE has been resulted in the death of 
the patient, then as Pharmaceutical Company we have an obligation to report the Regulatory 
Authorities within 15 days of the receipt of the information and if the event is less are severe we 
are expected to report this information to the health authority within 90 day of the receipt.   
 
As part of my job responsibility, while reviewing ADRs that we receive from the 
healthcare professionals (HCPs), don’t adhere to the Pharmacovigilance reporting requirements 
(Shamim, Sharib, Mahi, & Raza, 2016). HCPs play an important role in detection, assessment 
and spontaneous reporting of the adverse event reactions. Pharmaceuticals companies play a 
vital role in educating the HCPs and their practice regarding ADR reporting and 
Pharmacovigilance. We often see that the HCPs don’t adhere the pharmacovigilance 
requirement, provide insufficient data to the ADR’s and don’t have knowledge where to report 
information. It’s mainly due to lack of knowledge and consider ADR reporting as a time 
consuming process. So, that’s motivated to choose this topic if the pharmacovigilance training 
provided to the HCPs whether or not would improve their knowledge, attitudes towards the 
ADR reporting. This will help the Pharmaceutical Company to see whether benefit risk profile 
of the drug is changed when compare to the pre clinical setting and whether new risks were 
been identified through and ensure that companies have enough risk minimization measures in 
situation such as as updating the label of the product or educating HCPs or care givers about 
new risks associated of the product (Maeda, Katashima, Ishizawa, & Yanagawa, 2015) (Mehta, 
M Dheda, & Steel, 2014).  
 
Laws govern the pharmaceutical companies and regulations to ensure the companies 
have proper processes and procedures in place and to ensure the safety of the product (Foreman, 
2013). It is mandatory for some of the employees working in the company are subjected to 
training. In the most of the pharmaceutical companies the training is provided through the 
paper-based system. But when the organization grows geographically it would pose a 
challenging problem to the company. So its always better if the company switch to the 
computer based system to maintain productivity. For computer based learning, electronic 
learning management system is required and FDA has mandated that system have to be in 
compliance with 21 CFR part 11 Code of Federal Regulations (Foreman, 2013). This regulation 
specifies the FDA guidelines on electronic records and electronic signatures in the United 
States. Part 11, as it is commonly called, defines the criteria under which electronic records and 
electronic signatures are considered to be trustworthy, reliable and equivalent to paper records. 
In order to develop such complex systems would require lot of planning, inputs from end users, 
cross functional departments and resources. So to develop the electronic LMS, traditional 
waterfall methodology approach has been the most successful. For the implementation of 
Learning Management system consists of following steps. 
 
3.0 Problem Statement and Justification 
The literature review shows that that ADR is causing significant impact on the global health 
system, which needs to be, addressed around the globe and as well the different levels of the 
health care system. The main reason behind this is due to the lack of awareness among HCPs 
and Caregivers and impact of the problem. Also, misclassification of the ADRs as other non-
drug- related diseases or symptoms of the underlying condition. (Mehta, M Dheda, & Steel, 
2014) 
 Even regulatory authorities around the global have implement certain methods and 
important of Pharmacovigilance problems required to be addressed. Per (Mehta, M Dheda, & 
Steel, 2014) half of the ADRs could be preventable occurring in the patients with improved 
prescribing, monitoring and adherence to the Pharmacovigilance requirements. Improving 
knowledge and awareness among at different level of health care system professionals would 
benefits the Pharmacovigilance and address the current scenario and helps to prevent occurring 
the ADRs among patients. The literature indicates shows that Pharmacovigilance ADR 
reporting would help the companies to propose the risk minimization to prevent occurring of 
same AEs or ADRs related to the product and protects the patients from untoward harmful risks 
of the drug. The spontaneous and voluntary reporting of ADRs information is relatively new 
and for Serious ADR reporting, company rely on the HCPs to identify and report the suspect 
ADRs to Regulatory authorities or to the manufacturer of the medicine. HCPs are the primary 
contributors of ADR reports and would play crucial role in identification, detection and 
assessment reporting of ADRs.  
 Pharmaceutical companies have obligation to continuous monitor the ADRs raised post 
marketing experience whether the ADRs impacting the benefit risk profile of the drug and 
implement risk minimization measures like educating the HCPs on the new risks associated 
with the product. However, it’s always been a challenging problem for the Pharmaceutical 
companies because of the lack of knowledge of ADRs reporting among HCPs and reporting 
incomplete information to the Pharmaceutical companies that doesn’t help them to propose 
steps to prevent the ADRs. Current knowledge and awareness among the HCPs has to be 
addressed (Alan, Melike, Sule , Burcu, & Yusuf , 2013). As most of the ADRs occurrence can 
be preventable with proper prescribing, administration, adherence and monitoring.  The proper 
knowledge and training around pharmacovigilance reporting could bring awareness among 
HCPs and their perception towards ADR reporting. Pharmacovigilance is the best approach in 
preventing the occurrence of ADRs and AEs to protect patient well being safety and drug 
safety. An experimental has been proposed to determine whether or not the pharmacovigilance 
training provided to the HCPs would improve their knowledge and awareness among HCPs 
regarding the ADR reporting. The training will be provided through the electronic learning 
management system. The other objectives of of the study that pharmaceutical company can play 
an important role in increasing the knowledge of the HCPs, their attitudes towards ADR 
reporting and benefits of the ADR reporting which will the people from untoward occurrence of 
ADRs and well being of patient and product.  Other underlying reasons are socio-economic 
concerns from ADRs, and the clear need of involvement of HCPs in the well structured 
program for monitoring ADRs (Maeda, Katashima, Ishizawa, & Yanagawa, 2015).  
The literature review indicates, for the successful implementation of the electronic LMS 
traditional waterfall methodology is the right choice. The questionnaire and training will be 
provided through the electronic LMS. Before actual study a pilot, project will be conducted to 
test overall adequacy of the questionnaire and to understand what problems could be raised. So, 
that the problems could be prevented in the actual study (Mehta, M Dheda, & Steel, 2014) (kc, 
Tragulpiankit, Gorsanan, & Edwards, 2013). 
 
4.0 Literature Review 
 
In current world, the new medicine has changed the way the disease perspective and has been 
controlled. However, there should be common process in places in minimizing the event of 
adverse reactions to medicines such as disability, prolonged hospitalization and in the event of 
death (Mehta, M Dheda, & Steel, 2014). 
 
A best example for this is the Thalidomide tragedy that occurred in the 1960’s that led 
to the congenital abnormality in the newborn neonates to the mother who used the product 
Thalidomide to treat morning sickness during pregnancy. Due to proper lack of timely reporting 
events led to the linkage between the effects of product and which is resulted in the congenital 
abnormality and delayed responsible for the conclusion of Thalidomide introductions. Though 
this could have been prevented if proper reporting channels would have been in place by 
informing the patients to know about the adverse events associated with use of the medicines 
(Jha, Rathore, & Ravi Shankar, 2014).  
 
Due to this major break out this had become the modern starting point of science focused on 
the patient problems caused by the use of the products in the market. This new branch of 
science and activities related with it is known as “Pharmacovigilance”. 
According WHO definition the Pharmacovigilance is defined as the science and activities 
related 
• Detection 
• Assessment 
• Understanding and prevention of AEs or any other drug related problem (EMA, 
2012). 
The objective of the Pharmacovigilance to improve the patient care and patient safety in related 
to use of the medicines and to support the patient through the patient programmes by providing 
benefit risk profile of the products to the patients (EMA, 2012). The main priorities of any 
Pharmaceutical companies is to safe guard the patients and safe use of the medicines. The main 
objective of Regulatory agency and Pharmaceutical Company is to ensure the quality, efficacy 
and safety of the all the products available in the market. They do based on the two criteria 
through the data received from the in vitro studies through by ensuring the compliance of the 
standards and data received from animal preclinical and clinical studies in the humans (EMA, 
2012). 
 
Though the products in clinical settings but doesn’t have a power a to detect all rare 
ADRs. Since because in the premarket clinical trials doesn’t give full safety profile of the drug 
and so in this view Pharmacovigilance plays an important role in establishing the safety profile 
of the marketed drugs (European, 2014). In order to improve the Pharmacovigilance process the 
drug safety regulations laid by the health regulatory agency is often gets updated in order to 
improve patient safety and to prevent or minimizing the prevalence of the ADRs. Nonetheless, 
its remains problem if there is lack of reporting and knowledge about the Pharmacovigilance 
(European, 2014). 
 
Adverse Drug Reactions: 
The main objective of the Pharmacovigilance is mainly related with the reporting of the ADRs. 
As per the definition of the WHO ADR is defined as a response to medicine in humans or 
animals, which is unintended and noxious including the lack of efficacy that occurs at any 
dosage and can also be due to misuse, overdose and abuse. Adverse event (AE) is any 
undesirable experience associated with the use of the medicinal product in human (kc, 
Tragulpiankit, Gorsanan, & Edwards, 2013). Per the literature review ADR and AEs are 
common problems due to the pharmacotherapy and which are main reason for the congenital 
anomaly, morbidity and mortality around the world. In some countries ADRs are categorized as 
a top ten for the leading causes of the mortality. Per the research studies conducted at various 
parts of the world containing 41900 patients and identified that approximately 6.7% of all the 
hospitalization were due to ADRs (Mehta, M Dheda, & Steel, 2014). Below are the statistics 
from the countries were AEs accounted for hospitalization (Mehta, M Dheda, & Steel, 2014)  
• 3.2 % in France 
• 6.7% in the USA 
• 12% in Sweden 
• 6.5% in the UK 
The studies conducted by Metha (2014) showed for managing ADRs it causing significant 
burden on the Health care. Per the literature review, some countries are spending 15% of their 
budget to manage drug related issues. So, due to ADRs pose more burden on the health care 
system as they lead to prolonged hospital stays and increase cost of the treatment.  
ADR reporting: 
The success of the Pharmacovigilance depends upon the suspected ADR reporting process. The 
ADR reporting process can be done by two methods 
• Voluntary 
• Spontaneous reporting 
 
Spontaneous reporting is considered as the most common method and the keystone for 
any Pharmacovigilance system (European, 2014).  
The two reporting system are considered as the essential components of the drug safety 
surveillance system and are the most effective methods of collecting ADRs especially in case of 
the new and serious ADRs. This type of reporting lies within in the HCPs identify and report 
suspected ADRs to the respective health authorities or the pharmaceutical companies that own 
marketing authorization for the product. 
Though the process is considered as vital role for the reporting but under reporting is the most 
outcome for the spontaneous reporting system (European, 2014). The underreporting system 
will impact majorly on the safety profile of the product which delays in identifying the ADRs 
and can increase risks of drugs related morbidity and mortality rate. Overall, under reporting of 
the ADRs is common and significant problem for developing effective drug safety surveillance 
programs for products.  
Under –reporting by HCPs 
Per the several studies in the literature shows that HCPs play a vital in role in the identifying, 
assessment and spontaneous reporting of the ADRs. To understand the reasons for the under 
reporting there were number global conducted to assess their attitude and behavior towards the 
regulatory program and their ADR reporting program with aim of recognizing reason of 
underreporting and the steps to evaluating the steps to improve the increase reporting rates 
(Peter , Hervé , Yola , & Conti, 2016).  Based on the studies conducted and here are the 
summarize of the various studies due lack of resources for drug safety surveillance and 
reporting, Labor intensive and time consuming for reporting processes, ambiguity in 
interpreting whether the AE is in relationship to the product, ignored about the official 
procedures, ADRs are mistakenly considered significant to report, no reward and motivation to 
report and lack of knowledge to differentiate between ADRs and minor ones. 
Based on the several studies to assess the knowledge, attitude and practice between HCP and 
results show that their knowledge regarding reporting procedures is inadequate. The only way 
to improve their knowledge is to provide continuous training about the products and make them 
familiar to the ADR reporting process and change their attitudes and beliefs (Alan, Melike, Sule 
, Burcu, & Yusuf , 2013).  
Improving HCP’s pharmacovigilance awareness:  
Health Authorities, Pharmaceutical Companies and HCP play a vital role in protecting the 
patients from the harmful effects of the medicines. This would be the shared responsibility by 
each of them to understand the risks associated with the medicines and have proper process in 
places in minimizing or managing the risks associated with use of the products.  
Raising awareness of the important risk associated with the medicines directly or 
indirectly and gives brief information about the benefits related to the product will help 
addressing the drug-induced diseases. Lack of maintaining such vigilance system would impact 
more and even sometime fatal consequences as well.  The HCPs should know about benefits 
and risks associated to the medicines (Peter , Hervé , Yola , & Conti, 2016). The HCPs should 
inform to the patients about the benefit and risks profile of the medicines and give clear 
instruction about the use of the medicines. HCPs should also broader knowledge about the 
pharmacovigilance and ADR reporting process to effectively minimize the drug related 
reactions (Bowers, 2011). HCPs need to know their role and responsibility for the following 
• Detection 
• Management 
• Documentation 
• ADR reporting process 
The role of Pharmaceutical companies to educate HCPs Pharmacovigilance awareness: 
Drug safety system is now considered as the integral part of the pharmaceutical companies. The 
current regulatory framework shows the Pharmacovigilance is considered as the crucial and 
categorized them as the organizational obligation. Improving the knowledge about the benefits 
of the pharmacovigilance could change the perception and considered it as the fundamental 
position (European, 2014). Pharmaceutical should have generalized process and standards about 
the awareness of the pharmacovigilance among companywide employees by creating certain 
norms and training all employees on the process and procedures. The companies should have 
proper pharmacovigilance system that makes awareness around the benefits of those systems, 
which may help HCPs effectively maintain patient’s safety and ensuring that patients are free 
from the harmful effects of the medicines.  
Role and responsibility of Pharmaceutical Companies.  
The main objective of the Pharmaceutical companies is to ensure the marketed products are safe 
and effective use for the human. The Pharmaceutical companies should proper risk management 
systems to evaluate continuously about safety -risk profile of the products. This could be 
achieved only when proper pharmacovigilance systems are in places. Pharma companies have 
obligation to continuously monitor their product use and AEs received from the resources and 
to detect, assess and evaluate the ADRs to understand the and prevent the ADRs by having 
better risk management systems. In order to achieve this regulatory agency have developed 
certain framework for Pharmacovigilance standards the company should have to established 
such as 
1) Having a responsible contact person for the product in the European area and will acting 
as liaison between the Pharmaceutical Company and Regulatory agency. 
2) Immediate actions should be taken when the serious ADRs identified related to the 
product 
3) Benefit -risk profiles ratio of the product should be continuously informed to the 
regulatory agency. 
The Companies should have to work together with other stakeholders such HCPs; Patient 
Support Programmes to make sure the safety of patient is compromised using the medicines 
(European, 2014). 
A strong Pharmacovigilance System: 
Companies should have strong pharmacovigilance system to identify and assess the ADRs 
received from the different resources and have proper process in place for addressing them. 
In developing countries and poor countries, Pharmacovigilance systems are not well established 
with in the companies and often seen to detect the ADRs related to the products. The 
Pharmacovigilance system should include the following 
• Should continuous monitor the risks and benefits of the drug 
• Give proper information to the patient about the safe use of the drug and associated risks 
related to drug (Bowers, 2011). 
• Need to have proper process for training to the HCPs and their effective communication 
with the patients on the use of the medicines. 
• Ensuring the nurses and health care professionals are aware about the 
Pharmacovigilance reporting process.  
The companies should motivate the HCPs to more vigilant while prescribing the drugs to 
the patients and monitor them continuous about the use of medicines. A strong 
Pharmacovigilance system helps in identifying the AEs that have not been seen in the clinical 
setting and evaluating the effectiveness of the product. This system will help in decreasing the 
incidence of the morbidity and mortality. The Pharmacovigilance is considered as effective only 
when the ADRs related to the products are managed appropriately and the safety profile of the 
drug remained same from pre-clinical setting to the clinical setting.  
Implementation of Electronic Learning Management System: 
Upon literature review, the successful implementation of Learning Management System 
Traditional waterfall methodology has been proven and widely used methodology in the 
pharmaceutical companies. For the implementation of Learning management system requires 
following are key essential steps for selecting right product (Foreman, 2013).  
 
For the selecting the right product for the company, requires inputs from cross-functional 
stakeholders and the inputs from the management team. This requires a proper planning and 
inputs from the current paper based training groups about the requirements. The requirements 
gathering should do properly before the selection of the product. For successful implementation 
of the LMS right resources are selected which is the crucial step Organizations that lack 
appropriate planning and resources risk a string of unwanted surprises, extensive delays, and 
problems that are likely to result in unhappy users. Once resources are identified, through 
traditional waterfall methodology following steps should be followed (Foreman, 2013). 
 
The further literature review will be conducted to understand what possible timelines for the 
implementation of LMS.  
 
                                      
5.0 Methodology 
Per the available literature and results shown that ADR has been significant problem that is 
accounting for the hospitalization in some of the countries and also causing significant burden 
on the healthcare system. As the problem has been arising only due to lack of awareness about 
the effects and severity of the problem (Koh, 2014).  
The Pharmaceutical more rely on the ADR reporting process and HCPs plays an 
important role in the detection, assessment and evaluating the ADRs. The only thing is to 
improve their knowledge, attitude and perception in reporting the information and towards and 
Pharmacovigilance. 
The research design that have chosen for this research proposal is to evaluate whether 
the training provided to the HCPs would improve their knowledge, attitude towards reporting of 
the ADRs.  A quantitative research study design methodology will be used for evaluating the 
results. A traditional waterfall methodology will be used for the implementation of the 
electronic LMS (Foreman, 2013). Upon literature review shown that, waterfall methodology 
has been successful method for the implementation of LMS.   
A quasi-experimental research method will be used to evaluate the HCPs knowledge. A 
total of 40 HCPs, which includes General Physician or Research Nurse, will be the participants 
in the study. All the participants are divided in two groups. Each group will have equal number 
of participants in the study. The experimental group gets the Pharmaceutical Pharmacovigilance 
training interventional and control group will not receive the training. To assess the knowledge 
of the HCPs each group will receive the questionnaire before and after the pharmaceutical 
pharmacovigilance training intervention. At the end of the study the results will be analyzed to 
determine the pharmacovigilance training provided to the experimental group whether or not 
improved their knowledge, attitude towards Pharmacovigilance ADR reporting.  
 
Objectives of the Research Study:  
 
The Main aim of the research study is to evaluate whether or not training provided by the 
companies would increase the HCPs knowledge towards ADR reporting. Also, determines the 
significant role of the companies can play in improving the knowledge of HCPs around the 
importance of ADR reporting and safety of the medicines.  
To determine the training provided would help in changing attitudes of the HCPs 
towards the pharmacovigilance reporting and increase their knowledge towards the 
pharmacovigilance system (Patidar, Rajput, Nirmal, & Savitri, 2013). The initial experimental 
design has three phases 
 
Experimental Design: 
In order to evaluate if the Global Pharmacovigilance product and patient safety would bring the 
awareness in the HCPs regarding the ADR reporting and their attitudes a qualification test will 
be done pre-and post-test design.  
Here are the following phases would be included.  
• Observation Point 1(also known pretest) 
• Intervention- Pharmacovigilance training 
• Observation Point 2(Post test) 
 
If a difference in the results pre-test and post-test, then one would expect it would be the 
intervention of the Pharmacovigilance training provided by the Pharmaceutical company. 
Though this approach good idea but need to have a control groups because we cannot come to 
conclusion the results are due to Pharmacovigilance training may arise from memory bias. So, a 
control group is included and utilizes a quasi-experimental research design (Mehta, M Dheda, 
& Steel, 2014).  
 
• Non-random experiment group 
• observation study point 1  
• Intervention 
• Observation study point 2 
• Nonrandom control group 
• Observation study point 1  
• No intervention 
• Observation study point 2 
 
So, the groups are divided into two and both are required to complete an initial 
questionnaire in the LMS which has set of ADR reporting and Pharmacovigilance questions to 
complete. Once the observational point 1 is finished then the non-random experimental groups 
got Pharmacovigilance training and other hand control group did not receive any training. After 
the two weeks, then at the post step or observational study point 2 the groups were to take again 
the same pharmacovigilance questionnaire.  
The Questionnaire Design 
The HCP knowledge and their attitudes towards ADR reporting and Pharmacovigilance among 
all the research participants are assessed and participants completed the questionnaire by using 
pen and paper. The questionnaires are used at different phases of the study discussed in the 
section 4.3 (kc, Tragulpiankit, Gorsanan, & Edwards, 2013).  
 
The Questionnaire consists of following sections.  
• Demographic information of the HCP 
• Question related to Pharmacovigilance 
• HCP practice 
• Prior experience in the ADR reporting process 
• Specialization of the HCP 
• Reasons for encourage or discourage ADR reporting 
• Problem faced while reporting ADR process. 
The following questionnaires are designed based on the literature reviewed, current job 
experience and the common issues identified in the underdeveloped and developed countries. A 
total 25 questions were framed to collect the information of the demographics, Knowledge and 
their attitudes regarding ADR reporting, prior experiences and issues they commonly face. 
Most of the questions are framed most of the different aspects of Pharmacovigilance and ADR 
reporting process. The questions are more centric to HCP viewpoint and their experience of 
ADR reporting (kc, Tragulpiankit, Gorsanan, & Edwards, 2013). The responses were most of 
them are measured on the Likert scale and consist of 
• Strongly disagree (=1) 
•  Disagree (=2) 
•  Neutral (=3) 
• Agree (=4) 
• Strong Disagree(=5) 
The questionnaire is reviewed by SMEs of the different companies and changes are made 
appropriate. The informed consent of the all the participants will be taken and confidentiality is 
ensured.   
 
Pilot Study 
A pilot study is conducted to test adequacy of the questionnaire. The questionnaire is will be 
complete to similar audience volunteer were to participate in the study. Based on the issues 
faced from the underlying pilot study can help to make necessary changes in the questionnaire 
and improved the overall study. The participants participated in the study are not participated in 
the actual study (Mehta, M Dheda, & Steel, 2014).  The only four questions included for this 
study. Based on the results some of the questions were modified and were reassessed again. The 
pilot study results were given boost to study.  
Pharmacovigilance training.  
Pharmacovigilance and HCP training a play pivotal role in this research study. 
Pharmacovigilance training would help in improving their attitude and their knowledge. The 
pharmacovigilance system is backbone for the pharmaceutical company to promote and 
understand the product knowledge that is on the market and under development.  
The pharmacovigilance trainings included the following sections (kc, Tragulpiankit, Gorsanan, 
& Edwards, 2013) 
1) ADR reporting timelines  
2) Importance of Pharmacovigilance 
3) History of Pharmacovigilance 
4) International Pharmacovigilance 
5) FDA regulatory guidelines 
6) Role of the Pharmaceutical Company  
7) Companies Pharmacovigilance system 
8) Role of HCPs 
9) Examples of Safety related and PQCs. 
 
Study Participants: 
The participants in the study were among the general physicians or working in hospitals. 
The total participants in the study are 20 and they will be divided into two groups, 10 in 
experimental group who received Pharmacovigilance training and other group 10 in control 
group who did not received pharmacovigilance training. Experimental groups received the 
Company named Y Pharmacovigilance training and training will be provided. (Peter , Hervé , 
Yola , & Conti, 2016). Before doing the training, take questionnaire will be asked to complete 
the questionnaire by both groups. A quasi-experimental research method will be used to 
evaluate the HCPs knowledge. All the participants are divided in two groups. Each group will 
have equal number of participants in the study. The experimental group gets the Pharmaceutical 
Pharmacovigilance training interventional and control group will not receive the training. To 
assess the knowledge of the HCPs each group will receive the questionnaire before and after the 
pharmaceutical pharmacovigilance training intervention. At the end of the study the results will 
be analyzed to determine the pharmacovigilance training provided to the experimental group 
whether or not improved their knowledge, attitude towards Pharmacovigilance ADR reporting.  
 
Statistical analysis: 
The results obtained from this research were analyzed after the end of the training. The effect of 
the pharmacovigilance training would be analyzed based on the pre test and posttest between 
the two groups. The data would be analyzed to understand the difference in pharmacovigilance 
knowledge after the end of the study.  
Questionnaire Examples:  
1) Please specify your gender 
a) Yes 
b) No 
2) Please provide your age 
a) 20-25 
b) 35-40 
c) 50-60 
d) 50-67 
 
3) Qualification details 
a) Doctor 
b) Pharmacist 
 
4) How many years of experience in your field 
a) 4 
b) 5 
c) 7 
d) 8 
 
5) Do you do browsing in Internet? 
a) Yes 
b) No 
 
6) Do you aware of Pharmacovigilance 
a) Yes 
b) No 
 
7) Have you ever reported ADR? 
a) Yes 
b) No 
 
8) Have ever trained on Pharmacovigilance training by any company? 
a) Yes 
b) No 
 
 
9) ADR reporting can only be done by 
a) HCPs 
b) Pharmacists 
c) Both 
10) Please indicate your gender: 
a. Male 
b. Female 
11) Please provide your age in years: a.     
a. 24 – 30 
b.    31 – 40 
c.    41 – 50 
d.    51 – 60 
e.    Above 60 
 
12 Professional qualification 
a. Doctor 
b. Pharmacist 
c. Nurses 
13 Please state your years of experience in your field  
a.    1 – 5 
b.    6 – 10 
c.    11 – 15 
d.    16 – 20 
e.    Above 20 
 
14 Do you have internet access 
a. Yes 
b. No 
15 Are you aware of the term Pharmacovigilance? 
a. Yes 
b. No 
16 What do you think Pharmacovigilance is? 
a. Detection and reporting of any unintended effect of a pharmaceutical 
product occurring at normal dosage which is related to the 
pharmacological properties of the drug 
b. Reporting of any unintended effect resulting from the use of a 
pharmaceutical product to the Pharmaceutical Company that 
manufactures the pharmaceutical product. 
c. The science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other drug‐
related problem. 
 
17 What do you think pharmacovigilance aims to assess? 
a. Safety over efficacy 
b. Efficacy over safety 
 
18 An Adverse drug reaction is defined as: any untoward medical occurrence that 
may present during treatment with a pharmaceutical product but which does 
not necessarily have a causal relationship with this treatment( WHO) 
a. True 
b. False 
 
19 ADR reporting can be done by 
a. Healthcare Professionals 
b. Patients 
c. Both 
 
20 Which of the following defines a serious adverse event? 
a. Life threatening 
b. Disability 
c. Death 
d. Hospitalization 
e. All 
 
21 With regards to ADR reporting, please mark the statement that best describes 
your reporting experience: 
a. I have never reported an ADR before 
b. I have reported the ADR to the Hospital Institution where I work 
c. I have reported the ADR to the Pharmaceutical Company 
d. I have reported the FDA 
e. I have reported to other Health Care Professionals 
 
22 Are you aware that you can report ADR’s to the FDA? 
a. Yes 
b. No 
 
23 Have you ever reported and ADR or side effect to a Pharmaceutical company? 
a. Yes 
b. No 
 
24 Have you recently come across a side effect that you felt was 
strange/new/serious and wished to report it to the Pharmaceutical company 
a. Yes 
b. No 
 
 
Statements Level of agreement 
Strongly 
agree 
Agree Not sure Disagree Strongly 
disagree 
Do you know how to report ADR      
Are you aware of any procedure how to 
report ADR 
     
Do you think one ADR report will make 
any differrence  
     
Do you think managing patient reporting 
more than ADR reporting 
     
Do you have time to report ADR      
Do you think ADR reporting takes more 
time 
     
Do you Pharmacovigilance is important as 
already its known ADR 
     
I provide training, will you be able to 
report an ADR.  
     
Do you aware the benefits of the ADR 
 
     
Do think ADR reporting is part of my 
professional responsibility 
     
Do you think Pharmacovigilance is 
overrated system? 
     
Do you thinks HCPs need to be provided to 
training Pharmacovigilance 
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 Statements Level of agreement 
Strongly 
agree 
Agree Not sure Disagree Strongly 
disagree 
29 Healthcare professionals need to 
increase ADR 
reporting to effectively prevent 
avoidable, harmful drug reactions 
     
30 Do you think success or failure 
depends on ADR reporting 
     
32 Pharmacovigilance won’t lead to 
fewer ADR’s 
     
33 Have you ever received training 
on the Pharmaceutical company 
     
 
 
6.0 PROPOSED WORK PLAN 
My plan is to initiate project kick meeting early summer i.e from 21-Jun-2017 and end 
around 21-Jan-2018.  Before starting the activities related to the project I would consider 
what resources might be needed for the successful implementation of the project. Below 
are the proposed plan dates for the project. 
 
Activity  Responsible 
Person 
Start Data End date 
Prerequisites  
Set Kick-Off meeting 
PM and 
Company 
Stakeholder 
sponsor  
21-Jun-2017 21-Jun-2017 
Agree on Objectives PM and 22-June-2017 22-Jun-2017 
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Company 
Stakeholder 
Sponsor 
Initiation- Requirements and 
Human Resource Planning 
PM, HR  26-Jun-2017 28-Jul-2017 
Logistic resources like 
hardware, access to databases 
ProQuest, company online 
journal resources 
PM and HR and 
relevant SMEs 
01-Aug-2017 01-Sep-2017 
Activities related to Literature 
review 
SMEs like SAS 
programmer, 
Risk 
Management 
Manager, 
Compliance 
specialist 
02-Sep-2017 06-Nov-2017 
Development of Questionnaire All SMEs and 
Project Manager 
07-Nov-17 18-Dec-17 
Pilot Project demo  PM 19-Dec-17 20-Dec-17 
Any changes to Pilot Project PM and SMEs 21-Dec-2017 26-Dec-17 
Finalization of Pilot Project 
Questionnaire 
PM and Risk 
Management 
Manager 
28-Dec-2017 29-Dec-17 
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Recruitment of Research 
Participants 
PM and Risk 
Management 
Manager 
02-Jan-2018 05-Jan-2018 
Initiation of Pilot Project Risk 
Management 
Manager 
08-Jan-2018 09-Jan-2018 
Analyzation of the data 
generated from test and Results 
Risk 
Management 
Manager and 
Statistical 
Programmer.  
10-Jan-2018 12-Jan-2018 
To discuss problems of the 
pilot project and questionnaire 
changes if applicable  
PM and all 
SMEs 
15-Jan-2018 18-Jan-2018 
Develop final research 
questionnaire 
SMEs Risk 
Management 
Manager and 
Medical 
Advisors 
19-Jan-2018 28-Feb-2018 
Research participant’s 
recruitments for actual research 
study 
PM and all 
SMEs 
28-Feb-2018 16-Mar-2018 
Initiation of the actual research Risk 19-Mar-2018 19-Mar-2018 
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study  Management 
Manager & 
SMEs 
Intervention of 
Pharmacovigilance training  
Risk 
Management 
Manager and 
Medical 
Advisors 
19-Mar-2018 23-Mar-2018 
Retest the knowledge of 
Participants   
Risk 
Management 
manager 
02-Apr-2018 02-Apr-18 
Analyse the Research study 
data  
SAS 
programmer 
03-Apr-2018 06-Apr-2018 
Results PM and Risk 
Management 
09-Apr-2018 10-Apr-2018 
Results shown to stakeholder 
or sponsor 
PM 16-Apr-2018 16-Apr-2018 
Completion of the project  PM 17-Apr-2018 17-Apr-2018 
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